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Abstract: Malignant Mesothelioma (MM) is a tumor of the serous membranes linked to exposure to
asbestos. A chronic inflammatory response orchestrated by mesothelial cells contributes to the
development and progression of MM. The evidence that: (a) multiple signaling pathways are
aberrantly activated in MM cells; (b) asbestos mediated-chronic inflammation has a key role in
MM carcinogenesis; (c) the deregulation of the immune system might favor the development of
MM; and (d) a drug might have a better efficacy when injected into a serous cavity thus bypassing
biotransformation and reaching an effective dose has prompted investigations to evaluate the effects
of polyphenols for the therapy and prevention of MM. Dietary polyphenols are able to inhibit cancer
cell growth by targeting multiple signaling pathways, reducing inflammation, and modulating
immune response. The ability of polyphenols to modulate the production of pro-inflammatory
molecules by targeting signaling pathways or ROS might represent a key mechanism to prevent
and/or to contrast the development of MM. In this review, we will report the current knowledge
on the ability of polyphenols to modulate the immune system and production of mediators of
inflammation, thus revealing an important tool in preventing and/or counteracting the growth
of MM.
Keywords: malignant mesothelioma; inflammation; immune system; ROS and RNS;
polyphenols; asbestos
1. Introduction
Malignant Mesothelioma (MM) is a rare primary tumor arising from the mesothelial cell linings
of the serous membranes, most commonly involving the pleural and peritoneal spaces [1]. The
development of MM consists of a multi-step process driven by cellular DNA damage and tumor cell
promotion, in which genetically modified mesothelial cells are prone to grow, and tumor progression,
in which mesothelial cells develop a more aggressive phenotype and eventually acquire the ability to
metastasize and invade other tissues. The immune system’s involvement in the development of MM is
complex and multifaceted and is likely to involve both the innate and adaptive immune systems [2–4].
A chronic inflammatory response orchestrated by mesothelial cells contributes to the development
and progression of mesothelial cells into MM [2–4].
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Cisplatin and antifolate-based combination chemotherapy represent the standard first-line
treatment for advanced and unresectable MM patients [5]. However, taking into account the poor
outcome and toxicity of chemotherapy, novel approaches based on targeting abnormally activated
signaling pathways in MM cells were employed to improve survival in MM patients, as described in
the review by Remon et al. [5]. Clinical trials have employed antiangiogenic and vascular disrupting
agents, PI3K/AKT/mTOR pathway inhibitors, heat shock protein S90 inhibitors and arginine depletory
molecule, and immunotherapy. However, although some of these clinical trials sustain further studies,
the absolute response rates (RRs) are limited compared to other tumors [5].
The knowledge of MM pathophysiology might influence novel approaches [6–9].
The evidence that: (a) multiple signaling pathways are aberrantly activated in MM cells [10];
(b) asbestos-mediated chronic inflammation through the release of reactive oxygen species (ROS),
nitrogen species (RNS) and cytokines has a key role in MM carcinogenesis [11]; (c) the deregulation of
the immune system might favor the onset of MM [9]; and (d) a drug might have a better efficacy when
injected into a serous cavity, thus bypassing biotransformation and reaching an effective dose [12],
have prompted investigations to evaluate the effects of polyphenols for the therapy and prevention of
MM. Dietary polyphenols possess pleiotropic properties capable of being able to (a) inhibit cancer cell
growth by targeting multiple signaling pathways; (b) reduce inflammation and (c) modulate immune
response [13–17].
The ability to reduce chronic inflammation might represent a key mechanism to contrast the
development and/or to prevent MM. Accordingly, the local or systemic administration of polyphenols
might reduce the production of pro-inflammatory molecules by targeting signal transduction pathways
or ROS and RNS. In addition, the pro-oxidant activity of polyphenols could be a strategy to kill cancer
cells and thus to limit tumor growth [14].
In this review we will report the current knowledge on the ability of polyphenols to modulate the
immune system and production of mediators of inflammation in MM, thus revealing an important
tool to prevent and/or to counteract the growth of MM.
2. Polyphenols
Polyphenols, a large group of phytochemicals ubiquitously found in plants, are secondary
metabolites that perform functions in the host’s defense against pathogens, ultraviolet radiation,
and signal transduction [18]. Polyphenols are present in food and beverages of plant origin, such as
fruits, vegetables, cereals, spices, legumes, nuts, olives, tea, coffee, and wine [19]. These compounds
exhibit anti-inflammatory, antimicrobial, anticancer, and immunomodulatory activities, and thus are
beneficial for human health [20].
Polyphenols have a characteristic phenolic structure and are classified according to the number of
phenol rings that they contain and by the structural elements that bind these rings to one another. The
main classes of polyphenols are flavonoids, phenolic acids, stilbenes, and lignans [18,21].
Among flavonoids, the most important subclasses are flavonols, flavones, flavan-3-ols,
anthocyanins, flavanones, and isoflavones. The flavonoid subclasses dihydroflavonols, flavan-3,4-diols,
chalcones, dihydrochalcones, and aurones are minor components of our diet [22].
Quercetin, kaempferol, and myricetin, found mostly in fruits, edible plants, wine, and tea,
are the main flavonols [18]. The most abundant flavones in foods are apigenin (parsley, celery,
onion, garlic, pepper, chamomile tea) and luteolin (Thai chili, onion leaves, celery) [20]. The
flavan-3-ol subclass includes a wide range of compounds with different chemical structures that
can be divided in monomers, (+)-catechin, (´)-epicatechin, (+)-gallocatechin, (´)-epigallocatechin,
(´)-epicatechin-3-O-gallate, (´)-epigallocatechin-3-O-gallate, and polymers (proanthocyanidins) and
are found mainly in fruits, berries, cereals, nuts, chocolate, red wine, and tea [20]. The most
abundant anthocyanins (cyanidin, pelargonidin, delphinidin, peonidin, petunidin, and malvidin)
are found mainly in berries, cherries, red grapes, and currants [23]. Flavanones are present in
citrus fruit and the most important are hesperetin and naringenin and their correspondent glycated
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forms (naringin (naringenin-7-O-neohesperidoside), neohesperidin (hesperetin-7-O-neohesperidoside),
narirutin (naringenin-7-O-rutinoside), and hesperidin (hesperetin-7-O-rutinoside)) [21,24]. Daidzein,
genistein, and glyciten are the most common members of isoflavones, found mainly in soybeans, soy
products, and leguminous plants [25].
Among phenolic acids, the hydroxybenzoic acids (protocatechuic acid and gallic acid) are found
in few edible plants, while hydroxycinnamic acids (caffeic acid, ferulic acid, p-coumaric acid, and
sinapic acid) are found in fruits, coffee, and cereal grains [18].
The main member of stilbenes is resveratrol (3,5,41-trihydroxystilbene) and is present in
grapes, berries, plums, peanuts, and pine nuts [21]. Lignans (ecoisolariciresinol, matairesinol,
medioresinol, pinoresinol, and lariciresinol) are found in high concentration in linseed and in
minor concentration in algae, leguminous plants, cereals, vegetables, and fruits [18]. Curcumin
(1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), a member of the curcuminoid family,
is another polyphenol compound found in turmeric, a spice produced from the rhizome of
Curcuma longa [26].
Polyphenols have important anti-inflammatory effects by regulating innate and adaptive
immunity through the modulation of different cytokines and also by acting as an immune surveillance
mechanism against cancers through the regulation of apoptosis [14]. Polyphenols also possess
anti-oxidant and pro-oxydant activities [27–30] and are able to modulate multiple targets involved in
carcinogenesis through simultaneous direct interaction or modulation of gene expression [13]. It is
worth nothing that these compounds are able to inhibit the growth of cancer cells without having an
adverse effect on normal cells. In this way, polyphenols play selectively an antitumor role in cancer [14].
However, despite promising results obtained from in vitro studies, the use of polyphenols as anticancer
agents is yet limited in clinical practice due to their low bioavailability in the human body, which
affects the effective dose delivered to cancer cells. In fact, polyphenols have a poor absorption and
biodistribution and a fast metabolism and excretion in the human body. Only nano- or micromolar
concentrations of polyphenols and polyphenol metabolites are found in plasma (0–4 µM after an intake
of 50 mg of aglycone equivalents) [31]. Several mechanisms limit the bioavailability of polyphenols,
including their metabolism in the gastrointestinal tract and liver, their binding on the surfaces of
blood cells and microbial flora in the oral cavity and gut, and regulatory mechanisms that prevent
the toxic effects of high compound levels on mitochondria or other organelles [32]. In addition to
endogenous factors, dietary factors can affect the bioavailability of polyphenols, such as food matrix
and food preparation techniques [33]. Promising strategies for improving the in vivo anticancer effects
of polyphenols are the combination of polyphenols, or polyphenols and conventional cancer treatments,
and the intratumoral administration of polyphenols, in order to bypass biotransformation and reach
an effective dose directly available at the site of tumor [22]. Several pre-clinical and Phase I and Phase
II clinical trials are employing intratumoral administration to deliver different therapeutics such as
drugs, viral-based cancer vaccines, immune cell-based vaccines, cytokines, DNA, bacterial products,
nanoparticles, and natural compounds to the tumor site [34–39]. Thus, intratumoral delivery of cancer
therapeutics could be a more efficient route of administration for several agents in easily accessible
tumors, such as MM. An intratumoral route of administration is able to prevent the occurrence of
systemic side effects and makes the therapeutic agents directly available at the tumor site, allowing for
the highest concentration close to tumor cells [40].
3. Asbestos Fibers and MM
MM was broadly observed in the mid-to-late 1960s among workers whose asbestos exposure
began 30–40 years earlier [41]. Accordingly, the development of MM has been linked to exposure
to asbestos fibers [1]. Although the use of asbestos has by now been prohibited in 55 countries, the
occurrence of asbestos-related diseases cannot decrease due to: the long latency period of MM, the
continued use of asbestos in Third World Countries and the continued occupational exposure in
Western Countries, such as the US and Europe [5,42].
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Thermo-resistant magnesium and calcium silicate fibers were usually used as insulating materials
in buildings and are deposited in the alveoli upon inhalation. Asbestos fibers are genotoxic, causing
random chromosome breaks [43]. Asbestos is classified into two major categories (amphibole and
serpentine) [43]. There are five members of the amphibole category: crocidolite (blue asbestos), amosite
(brown asbestos), tremolite, anthophyllite, and actinolite. The serpentine class is made up of only one
member (chrysotile, white asbestos) [43]. The International Agency for Research on Cancer (IARC)
classifies asbestos as a Group I carcinogen, because of the ability of chrysotile, crocidolite, and amosite
to induce lung cancer or MM [44]. Fiber translocation into the pleural cavity can occur across the
alveolar surface or via pulmonary lymph flow [45].
Although the link between MM and asbestos is well established, other carcinogenic or
co-carcinogenic events must be involved in MM development because only 10% of all MM cases
occur in asbestos-exposed subjects [46].
4. Chronic Inflammation Affects MM Development
4.1. Overproduction of ROS and RNS
A key immune-mediated involvement in asbestos-related carcinogenesis is superimposed on
the fibers’ damage to the mesothelium integrity. Mesothelial cells offer the first defense against
chemical and biological injuries by building a mechanical barrier and also by activating inflammation
through the release of ROS, RNS, and cytokines [47–51]. In fact, mesothelial cells express on their
luminal surface a sialomucins veil that electrostatically repels bacteria, viruses, and chemicals and
mechanically decreases their adherence to the mesothelial layer [47]. In addition, serous spaces
are surrounded by several defensive molecules including lysozyme, IgA immunoglobulins, and
complement factors [47]. Mesothelial cells damaged by asbestos fibers release inflammatory mediators
that maintain an inflammatory environment [48–50].
Asbestos induces free radical production by mesothelial cells through the iron content of the
asbestos fibers which increases the hydroxyl radical formation from hydrogen peroxide through
iron catalysed reactions and by inflammatory cells such as pulmonary alveolar macrophages and
neutrophils [52]. Kinnula et al. reported that inflammatory cells are the essential cells responsible
for the free radical-mediated mesothelial cell injury during asbestos exposure in vivo [53,54]. During
the respiratory burst, leukocytes produce multiple ROS, including hydroxyl radical, superoxide
anions, and hydrogen peroxide [55]. Hansen et al. reported that the geometry and/or chemical
composition of asbestos is important for the release of superoxide anions by leucocytes during
frustrated phagocytosis [56,57]. Indeed, crocidolite and amosite induced significant ROS generation
by neutrophils with a peak at 10 min, whereas that of chrysotile was ~25% of the crocidolite/amosite
response [58].
Leukocytes and mesothelial cells are also able to overexpress nitric oxide synthase (NOS) in
response to a variety of stimuli [52]. Inflammatory cytokines and oxidant stress can each augment iNOS
expression and activity in pulmonary alveolar epithelial cells [52]. The inhalation of either chrysotile or
crocidolite asbestos fibers was shown to induce the production of nitric oxide in bronchoalveolar lavage
cells and the formation of nitrotyrosine within the lungs and pleura [59]. The majority of MM was
found to express high levels of iNOS, while its expression was occasionally found in non-neoplastic
healthy mesothelium [60]. Thus, RNS might have an important role in asbestos-mediated mesothelioma
oncogenesis [52]. Peroxynitrite can be produced by the reaction of ROS with RNS. The overproduction
of ROS and RNS in the inflammatory microenvironment can cause DNA damage to mesothelial cells,
thus leading to the development of MM [61].
Macrophages are recruited and activated to clear away asbestos fibers [48]. Vitronectin captures
crocidolite asbestos and enhances fiber phagocytosis by mesothelial cells via integrins [62]. Yang et al.
provided the mechanistic rationale that associates asbestos-mediated mesothelial cell necrosis to the
chronic inflammatory reaction that is, in turn, linked with asbestos-mediated tumorigenesis [63].
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The authors reported that exposure of mesothelial cells to crocidolite asbestos induces them to
activate poly(ADP-ribose) polymerase, to secrete hydrogen peroxide, to deplete ATP, and to secrete
high-mobility group box 1 protein (HMGB1) into the extracellular space. This latter stimulates
macrophages to secrete tumor necrosis factor-α (TNF-α) and the inflammatory response associated
with asbestos-mediated carcinogenesis [2].
The asbestos-mediated chronic inflammation can increase the genotoxic damage due to the
secretion of free radicals [48].
In addition, several studies have shown that asbestos fibers induce the activation of EGFR
(Epidermal growth factor receptor) and thus MAPK (Mitogen-activated protein kinase) pathway and
AP-1 (Activator protein-1), leading to cell proliferation [43] (Figure 1).
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IL-18 [65,66]. It was reported that the NLRP3 inflammasome is necessary for early inflammatory
responses to asbestos, but it is not indispensable for asbestos-induced MM [64]. Hillegass et al. linked
NLRP3 activation to the release of several pro-inflammatory cytokines (IL-1β, IL-6 and IL-8) and the
vascular endothelial growth factor (VEGF) by fiber-stimulated human mesothelial cells in vitro [63].
They showed that mesothelial cells secrete IL-1β in response to asbestos/erionite and that through an
autocrine stimulation they undergo transformation [63]. In addition, the authors demonstrated that
treatment of MM tumor-bearing SCID mice with IL-1R (Interleukin-1 receptor) antagonist (Anakinra)
decreased the levels of IL-8 and VEGF in peritoneal lavage fluid, thus indicating that IL-1 has a key
role in regulating the production of other cytokines, thus affecting the tumorigenesis of mesothelial
cells [63]. A combination of IL-1β and TNF-α and erionite, or at least two cytokines together without
erionite, for at least four months, induced transformation of the immortalized, non-tumorigenic human
mesothelial cell line (MeT-5A) in vitro [67].
Accordingly, the release of cytokines driving inflammation represents a hallmark of exposure
to asbestos. Mesothelial inflammatory processes were reported to occur both in animal models and
in the lungs of patients exposed to asbestos. The production of different cytokines by mesothelial
cells indicates the particular transcriptional aptitude of mesothelial cells [68]. A cytokine network
is established in the serous membranes after mesothelial cell injury. Among the other cytokines,
chemokines produced by mesothelial cells can recruit leukocytes [68] (Figure 1). Driscoll et al. showed
that alveolar macrophages release TNF-α and IL-1 in rats exposed to crocidolite fibers [69]. In
addition, crocidolite enhanced the production of mitochondrial-derived hydrogen peroxide which in
turn contributes to crocidolite activation of NF-κB and increased MIP-2 (Macrophage Inflammatory
protein-2) gene expression in rat alveolar Type II cells [70]. Recently, Acencio et al. performed
an in vitro experiment to determine the acute inflammatory response of mesothelial cells damaged
by asbestos fibers. They showed that mesothelial cells exposed to either crocidolite or chrysotile
produced high levels of IL-6, IL-1β, MIP-2 and that these cytokines, when acting together with
asbestos, increased cell death of pleural mesothelial cells [49]. Indeed, they showed that anti-IL-1β
and anti-IL-6 antibodies significantly inhibited necrosis and apoptosis of mesothelial cells exposed
to crocidolite [49]. High levels of cytokines, including transforming growth factor beta (TGF-β), IL-6,
IL-1 and TNF-α were produced during MM development in an in vivo mouse model by the MM
cells and/or tumor infiltrating leukocytes [71]. TNF-α, IL-6, TGF-β, and IL-10 have been shown to
participate in cancer initiation and progression [72]. TGF-β counteracts proliferation and differentiation
of different immune cells, thus inducing immunosuppression and favoring cancer cell growth [73].
IL-1β may confer a proliferative advantage to cancer cells through autocrine mechanisms [74]. The
pro-inflammatory cytokines IL-1β, IL-6, IL-8, and VEGF promote tumor angiogenesis [75].
Fox et al. investigated the expression of CC and CXC chemokine genes I response to cytokines in
MM and mesothelial cell cultures derived from two different mouse strains (BALB/c and CBA/CaH).
They found that monocyte chemoattractant protein-1 (MCP-1)/JE, GRO-α/KC and RANTES were
expressed in mouse MM and mesothelial cells, whereas MIP-1α and MIP-2 were infrequently expressed
in these cell lines. MCP-1 was up-regulated in response to TNF-α and other cytokines [76]. MCP-1 and
RANTES have been shown to induce cell growth and to act as monocyte attractants [77]. GRO-α/KC
mRNA was overexpressed in cancer cells [76].
In vivo human studies were performed as well. The study of the RENAPE (French Network for
Rare Peritoneal Malignancies) aimed to evaluate the intraperitoneal levels of IL-6, IL-8, IL-10, TNF-α,
and sICAM (soluble intercellular adhesion molecule) in patients with pseudomyxoma peritonei and
peritoneal mesothelioma. They found that cancer patients had significantly higher intraperitoneal
cytokine levels than non-cancer patients. Cytokines peritoneal levels were significantly higher in
peritoneal fluids compared with matched sera, thus indicating the cytokines production from either
peritoneal cells or immune cells. In addition, they found a correlation between cytokine peritoneal
levels and aggressiveness of peritoneal surface malignancies [78].
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Comar et al., employing Luminex Multiplex Panel Technology, measured the serum levels
of a large panel of cytokines and growth factors from workers previously exposed to asbestos
(Asb-workers). They found that interferon (IFN)-α, EOTAXIN, and RANTES were highly expressed in
Asb-workers while IL-12(p40), IL-3, IL-1α, MCP-3, β-NGF (nerve growth factor), TNF-β, and RANTES
were highly produced in MM patients [79].
Xu et al. found that the amount of CCL3 in the serum of healthy subjects potentially exposed to
asbestos was significantly higher than for the control group. In addition, they observed that the pleural
plaque, benign hydrothorax asbestosis, and lung cancer patients had serum CCL3 levels similar to
that of healthy subjects potentially exposed to asbestos. They detected the CCL3 chemokine in the
serum of nine of the 10 patients diagnosed with MM and three patients with MM showed very high
CCL3 levels [80]. The elevated levels of CCL3 are very likely produced by macrophages chronically
interacting with asbestos fibers [80].
4.3. Innate Immunity and Cytokines in the Development of MM: MM-Driven Immunoediting
The activation of an adaptive immune response and/or cell proliferation by inflammasome
effectors is dependent on the cell type and tissue microenvironment [81]. The creation of a local
cytokine-based microenvironment is employed by MM to avoid the specific immune response. IL-1β
and IL-18 released by epithelial cells promote a Th2 response and recruitment of suppressive immune
cells in the absence of IL-12 rather than activating Th1 and Th17 cells. In addition, the release
of growth factors will favor angiogenesis and tumor invasiveness [81]. Indeed, IL-1β promotes
carcinogenesis and induces the invasive potential of malignant cells by favoring the expression
of matrix metalloproteinases, VEGF, chemokines, growth factors, and TGF-β in chronic inflamed
tissue [82]. However, inflammasome’s activation in dendritic cells (DCs) and macrophages can
bias Th1, Th17 immune response ability to reduce tumor growth in the presence of an appropriate
microenvironment [81]. We recently demonstrated that macrophages and CD4+ T-cells were polarized
by MM to produce IL-17, and that this cytokine exerts multiple tumor-supporting effects on both cell
growth and invasiveness [83].
Many MM-derived factors can skew monocyte development through the recruitment of
tumor-supporting cells, as reported by the presence of myeloid-derived suppressor cells (MDSCs)
in murine models of MM. Employing a mouse model of transplanted diffuse MM, it was reported
that MDSCs arise simultaneously with the recruitment of inflammatory cells in tumor foci. The
presence of MDSCs came before the accumulation of macrophages and regulatory T lymphocytes
which suppress T-cell function [84]. The cytokine profile three weeks after MM injection induced a
tumor microenvironment that suppressed immune surveillance and antitumor immunity. At that
stage, high expression levels of CXCL12, a chemotactic factor for MDSC, CCL9, and CXCL5, were
observed [84]. Veltman et al. demonstrated that BALB/c mice carrying MM have PMN-MDSCs that
induce immunosuppressive activity by releasing ROS via a cyclooxygenase-2 (COX-2)-dependent
mechanism, which then induces T-cell immunosuppression [85]. The same authors inoculated mice
with MM cells and treated them with celecoxib, a COX-2 inhibitor. They observed that treatment
of tumor-bearing mice with the celecoxib prevented the local and systemic expansion of all MDSC
subtypes [86]. However, a recent study by Yang et al. also reported that aspirin (a COX inhibitor)
exerted a protective effect against MM growth through a COX-2-independent mechanism. In fact,
the authors demonstrated that aspirin inhibited MM growth in a xenograft model by inhibiting the
activities of HMGB1. The authors concluded that aspirin could be administered to people who were
exposed to asbestos or erionite to prevent or delay MM development and progression [87].
Tumor-associated macrophages (TAMs) represent a major link between inflammation and
cancer [88]. M1 macrophages have immunostimulatory Th1-activating properties while M2 cells
have poor antigen-presenting capacity and suppress Th1 adaptive immunity [88]. Prostaglandin E2
(PGE2), TGF-β, IL-6, and IL-10 promote M2 macrophage polarization. Inhibition of the antitumor
responses is achieved not only by the secretion of immunosuppressive cytokines but also by the
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selective recruitment of naive T-cells, trough CCL18, and of Th2 and Treg, through CCL17 and
CCL22 [88]. The majority of TAMs in MM have the M2 phenotype. By retrospectively reviewing 667
tumor specimens of patients with MM it was found that, within the tumors, macrophages comprised
27% of the tumor area and had an immunosuppressive phenotype [89]. Hegmans et al. detected in
pleural effusion of MM patients several cytokines involved in immune suppression and angiogenesis,
including TGF-β. In addition, they demonstrated that human MM tissue contained a high number
of Foxp3+ CD4+ CD25+ regulatory T-cells and when the CD25+ regulatory T-cells were depleted
in an in vivo mouse model, mice survival increased [90]. The expression profile of cytokines and
chemokines in mice transplanted with MM cells was consistent with M2-polarized cells [91]. They
found elevated IL-10 and IL-10RA expression as well as expression of CXCL13, CCL22, CCL24, and
their respective receptors [91]. In a recent report by Napolitano et al., it was also observed that mice
with germline BAP1 (BRCA1-associated protein-1) mutations (BAP1+/´ mice) exposed to low-dose
asbestos fibers had alterations in the peritoneal inflammatory response. In fact, BAP1+/´ mice showed
higher levels of pro-tumorigenic M2 macrophages and lower levels of M1 macrophages, cytokines
(IL-6, leukemia inhibitory factor), and chemokines (MCP-1, keratinocyte-derived chemokine). Thus,
these mice showed higher MM incidence after exposure to very low doses of asbestos, doses that
rarely induced MM in wild-type mice. The authors suggested that patients with this mutation have an
increased risk of developing MM, even after a minimal exposure of asbestos, due to alterations of the
inflammatory response [92].
Asbestos induces partially functional decreases in T helper (Th) cells, natural killer (NK) cells,
and cytotoxic T lymphocytes (CTLs) in patients with MM [93]. To elucidate the antitumor immune
interference of asbestos caused to CD4+ T-cells, Maeda et al. established an in vitro T-cell model
of long-term and low-level exposure to chrysotile asbestos from a human adult T-cell leukemia
virus-1-immortalized human polyclonal CD4+ T-cell line (MT-2). They observed a decreased expression
of CXCR3, IFN-γ, and CXCL10/IP10 in the MT-2 cell line, thus suggesting that exposure to asbestos
may impair the antitumor immune responses [94]. They also found that chrysotile asbestos reduces the
chemokine receptor CXCR3 expression in human peripheral CD4+ T-cells, thus suggesting that immune
response might be impaired in patients with asbestos-related disease because the low expression of
CXCR3 might reduce chemotaxis [95]. In addition, in a recent report, the same authors showed that
an asbestos-induced apoptosis-resistant subline (MT-2Rst), which was established from a human
adult T-cell leukemia virus-immortalized T-cell line (MT-2Org) by continuous exposure to asbestos
chrysotile-B, produced high levels of TGF-β1 through phosphorylation of p38 MAPK, and acquire
resistance to inhibition of cell growth by TGF-β1 [96]. It was observed that asbestos can trigger a
cascade of biological events including the increase of IL-10 expression and Bcl-2 overexpression in
human T-cell leukemia virus-immortalized T-cell line and that CD4+ T lymphocytes from MM patients
had significant up-regulation of Bcl-2 expression thus affecting their survival. The Bcl-2 up-regulation
might affect the Treg population thus contributing to immunosuppression in cancer patients [97]
(Figure 2).
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M2 phenotype. M2 TAMs have poor antigen-presenting capacity, suppress T-cells adaptive immunity,
and support MM growth.
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5.1. Effects of Polyphenols on ROS in MM
Epidemiological studies indicate the existence of an inverse correlation between the consumption
of polyphenols and the incidence of various chronic diseases and cancer. In fact, polyphenols
possess anti-oxidant activities and thus are able to protect cells from oxidative stress, providing
an anti-inflammatory effect [98–100]. For instance, flavonoids are able to scavenge ROS generated
by neutrophils and macrophages and to impair ROS production by inhibiting NADPH oxidase,
xanthine oxidase, and myeloperoxidase [27,29,30]. In addition, polyphenols modulate the activity
of ROS-generating enzymes, such as COX and lipoxygenase (LOX) [30,101,102]. Furthermore,
polyphenols inhibit NO production from activated macrophages [103,104] and also inducible nitric
oxide synthase (iNOS) protein and its mRNA expression [105].
However, polyphenols also possess a pro-oxidant activity, depending on their concentration and
chemical structure, cell type, or experimental conditions (pH, redox stress) [106,107]. The pro-oxidant
effect of polyphenols is important in cancer cells, since this effect leads to oxidative breaking of DNA,
inhibition of cell growth and apoptosis [14]. In fact, in the last few years the use of pro-oxidants against
cancer is an emerging topic of research, since it has been observed that ROS contribute to the cytotoxic
activity of some chemotherapeutics and that cancer cells are more susceptible to ROS than normal
cells [107].
As for MM, asbestos produces ROS and RNS, that act as second messengers to drive initiation and
progression of MM-carcinogenesis, through genetic alterations, activation of the survival pathways,
stimulation of matrix metalloproteinases (MMP), and angiogenic signaling. Furthermore, ROS mediate
extrinsic and intrinsic pathways of apoptosis, necrosis, and autophagy, thus ROS production is also
used as a therapy for MM, to limit tumor growth [51]. In this way, polyphenols, which also possess
pro- and anti-oxidant properties, are a promising tool to treat MM.
Several studies have explored the ability of different polyphenols as pro-oxidant agents in MM.
It has been demonstrated that curcumin (40 µM) increased ROS production in HMESO cells in vitro,
leading to caspase-1 activation and pyroptotic cell death of MM cells [108].
Satoh et al. demonstrated that the flavan-3-ol epigallocatechin-3-gallate (EGCG) induced ROS
production and impaired the mitochondrial membrane potential and these effects were responsible for
the induction of apoptosis in MM cells in vitro. In fact, the treatment of MM cells with ROS scavengers,
such as tempol and catalase, inhibited the apoptosis induced by EGCG [109]. A similar effect was
reported by Ranzato et al. They demonstrated that EGCG induced both apoptotic and necrotic cell
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death in MM cells. In particular, it has been shown that EGCG had a pro-oxidant effect and induced
cell death by the release of H2O2 outside of cells [110]. Similarly, a recent study showed that EGCG,
when added to culture medium, induced H2O2 formation and decreased proliferation both in MM
cells and MET5A cells (normal cells). Due to EGCG instability that causes H2O2 formation in culture
medium, ECGC was added to cells in presence of catalase (CAT) and exogenous superoxide dismutase
(SOD). In this way, EGCG decreased cell proliferation only in MM cells and induced mitochondrial
apoptosis [111].
The increased levels of ROS induce the nuclear translocation and activation of Nrf2 (nuclear factor
E2-related factor 2) in MM. Normally, Nrf2 is sequestered in cytosol by its inhibitor Keap-1 (Kelch-like
ECH-associated protein 1); when MM arises, the ROS levels increase and one or multiple cysteines
bind to Keap-1, which undergoes a conformational change releasing Nrf2. Next, Nrf2 translocates to
the nucleus and activates the transcription of downstream genes, as HO-1. The high levels of Nrf2
create an anti-oxidant environment which is resistant to MM-therapy. It has been demonstrated that
the combined treatment of clofarabine and resveratrol inhibited the Nrf2 pathway by reducing nuclear
localization of Nrf2 and by decreasing Nrf2 and HO-1 protein levels in vitro. Lee et al. hypothesized that
resveratrol with clofarabine decreased the chemoresistance of MM, modulating the levels of proteins
activated by ROS, as Nrf2 [112]. In addition, the same authors demonstrated that the combined
treatment of clofarabine and resveratrol increased the nuclear expression of phospho-p53. Hence,
p53 induced the expression of pro-apoptotic proteins, as Bax, Puma, and Noxa [113]. Faraonio et al.
indicated the possibility of crosstalk between p53 and Nrf2. p53 could prevent the generation of an
anti-oxidant environment counteracting the effect of Nrf2 and inducing apoptosis [114].
A recent study by Pietrofesa et al. reported the in vitro ability of LGM2605 (a synthetic lignan
secoisolariciresinol diglucoside) to reduce asbestos-induced cytotoxicity and ROS generation and to
induce phase II anti-oxidant enzymes stimulated by Nrf2 (HO-1 and Nqo1) in murine peritoneal
macrophages. LGM2605 acted as a direct free radical scavenger and anti-oxidant in a dose-dependent
manner. They hypothesized the possible use of this synthetic lignan as a chemopreventive agent in the
development of asbestos-induced MM [115].
Kostyuk et al. have conducted several studies on the efficacy of different polyphenols in preventing
asbestos-induced injury of peritoneal macrophages and red blood cells. They demonstrated that
quercetin and rutin were able to reduce peritoneal macrophages injury caused by asbestos and
to scavenge ROS. They suggested that quercetin and rutin could be promising drug candidates
for a prophylactic asbestos-induced disease [116]. Similarly, in another study they explored the
efficacy of the main polyphenolic constituents of green tea extract, (´)-epicatechin gallate (ECG)
and (´)-epigallocatechin gallate (EGCG). They observed that ECG and EGCG had a protective effect
against chrysotile and crocidolite-induced cell injuries in peritoneal macrophages, and this effect was
attributed to the scavenger properties towards the superoxide anion and the ability of polyphenols to
chelate iron ions [117]. They also concluded in a comparative study that the protective effect increased
in the following series: rutin < dihydroquercetin < quercetin < ECG < EGCG [118].
Effects of polyphenols on ROS in MM are summarized in Table 1.
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Table 1. Effects of polyphenols on ROS production and scavenging in MM.
Polyphenols Cell Type Effects on ROS Ref.
Curcumin H-MESO cells
Ò ROS
[108]Ò Caspase-1
Ò Pyroptotic cell death
EGCG
ACC-meso 1, Y-meso 8A,
EHMES-10, EHMES-1,
MSTO-211H, REN,
MM98, BR95, E198 cells
Ò ROS
[109–111]
Ò H2O2 outside of cells
Ò Apoptosis and necrosis
Ó Cell proliferation
Resveratrol
(+Clofarabine) MSTO-211H cells
Ó Nrf2 pathway
[112,113]Ò p53 phosphorylation
Ò Pro-apoptotic proteins
LGM2605
(a synthetic lignan)
Murine peritoneal
macrophages
Ó ROS
[115]Ó Cytotoxicity
Ò Phase II anti-oxidant
enzymes
Quercetin + Rutin Peritoneal macrophages
of Wistar rats
Ó ROS
[116]
Ó Peritoneal
macrophages injury by
asbestos
EGCG + ECG Peritoneal macrophages
of Wistar rats
Ó ROS
[117]
Ó Peritoneal
macrophages injury by
asbestos
Ó: decrease; Ò: increase.
5.2. Effects of Polyphenols on Mediators of Inflammation in MM
Inflammation plays a critical role in the process of carcinogenesis by regulating the different
stages of initiation, promotion, progression, and metastasis, and also the responses to therapies [119].
In this regard, it has been observed that the tumor microenvironment is infiltrated by innate and
adaptive immune cells, such as macrophages, neutrophils, mast cells, myeloid-derived suppressor
cells, dendritic cells, NKcells, and T and B lymphocytes that communicate to each other through the
production of cytokines [119].
Polyphenols possess the ability to directly modulate innate and also adaptive immune cells that
infiltrate the tumor. In fact, it has been demonstrated that different polyphenols, such as genistein,
EGCG, curcumin, and resveratrol, are able to modulate these immune cells to enhance an antitumor
response or to suppress the immune escape of tumors [14].
In addition, it has been demonstrated that polyphenols possess the ability to control the
inflammatory process by inhibiting the secretion of pro-inflammatory cytokines (IL-1β, IL-2, IL-6,
IFN-γ, TNF-α) and chemokines [20]. The inhibition of the production of these cytokines also led to
inhibition of ROS, since cytokines trigger ROS production [120]. Several studies have reported this
ability of polyphenols. For instance, curcumin and different flavonoids, such as flavones, EGCG, and
flavonols, are able to inhibit the secretion of TNF-α, IL-6, IL-1β, IL-8, and IFN-γ from various cell
types [121–129].
By the activation of different transcription factors, such as NF-κB, AP-1, STAT-3, SMAD, and
caspases, cytokines can promote or inhibit tumor progression [119]. It has been demonstrated
that polyphenols, such as resveratrol, flavones, flavonols, EGCG, anthocyanins, isoflavones, and
curcumin, are able to modulate NF-κB [130–138]. Curcumin, resveratrol, and EGCG also inhibit STAT-3
activation [139–142].
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Inflammation, and thus the production of inflammasome, has an essential role in the development
of MM [143]. As previously described, the active inflammasome induces the activation of caspase-1
and mature form of pro-inflammatory cytokines IL-1β and IL-18 and thus the inflammatory cell death
pyroptosis [144].
In this regard, the anti-inflammatory effect of polyphenols, by regulating innate and adaptive
immunity through the modulation of different cytokines, chemokines, and transcription factors could
be a promising strategy to contrast development of this type of cancer [14].
Miller et al. has observed that curcumin was able to kill MM cells via pyroptosis without the
classical inflammasome-related cytokines, IL-1β and IL-18. They observed that curcumin increased the
concentration of caspase-1 but did not increase IL-1β and IL-18 expression. Furthermore, they observed
a higher concentration of pro-IL-1β, indicating a block of the maturation of cytokine. Curcumin
treatment increased the expression of NLRP3, which alone induces a decreased NF-κB expression.
Curcumin reduced the inflammasome-related gene expression, NF-κB, TLR and IL-1 pathway. In
addition, curcumin down-regulated the expression of MYD88, NLRC4, and TXNIP and up-regulated
HSP90AA1 (heat shock protein 90 kDa alpha class A member 1), IL-12, IL-6. Hence, curcumin has an
anti-inflammatory effect on MM cells by blocking cytokine processing of IL-1β and genes involved in
the NF-κB pathway [108].
Wang et al. demonstrated that curcumin also suppressed MM cell growth in vitro and in vivo
(oral administration) and enhanced the efficacy of cisplatin. In particular, curcumin inhibited cell
growth through activation of p38 kinase, caspases 9 and 3, increased pro-apoptotic protein Bax levels,
stimulated PARP cleavage, and induced apoptosis. In addition, curcumin stimulated expression of
novel transducers of cell growth suppression, such as CARP-1, XAF1, and SULF1 proteins [145].
It has been shown that the activated NF-κB and high levels of the activated phosphorylated
STAT-3 are present in MM. Cioce et al. showed that butein (3,4,21,41-tetrahydroxychalcone), a natural
inhibitor of NF-κB and STAT-3, inhibits the migration of MM cells and strongly affects the clonogenicity
of MM cells in vitro by inhibiting the phosphorylation of STAT-3, the nuclear localization of NF-κB
and the interaction of NF-κB and phospho-STAT-3. Different genes involved in cancer progression of
pro-angiogenic cytokines (VEGF) and of IL-6 and IL-8 were also down-regulated. Furthermore, they
showed that butein was able to severely affect tumor engraftment and to potentiate the anticancer
effects of pemetrexed in mouse xenograft models in vivo. Intraperitoneal treatment with butein was
safe, since butein does not significantly affect the viability of human untransformed mesothelial cells
in vitro or the survival of tumor-free mice in vivo [146].
The activation of STAT-3 is associated to PIAS-3 expression levels in MM cell lines. PIAS-3
specifically interacts with phospho-STAT-3 and decreases the STAT-3 DNA-binding capacity and
transcriptional activity. The overexpression of PIAS-3 can inhibit STAT-3 transcriptional activity and
induces apoptosis in vitro [147]. Dabir et al. demonstrated that an inverse correlation between PIAS-3
and STAT-3 is present in MM cells. In fact, they showed that high levels of phospho-STAT-3 and low
levels of PIAS-3 are present. Furthermore, they observed that treatment with curcumin (1.0 µM) was
able to increase PIAS-3 levels and thereby decreased STAT-3 phosphorylation and cell viability in MM
cells [148].
Flaxseed lignans, enriched in secoisolariciresinol diglucoside (SDG), have been investigated for
the prevention of asbestos-induced peritoneal inflammation in a mouse model of accelerated MM
development that recapitulates many of the molecular, genetic, and cell-signaling features of human
MM after asbestos injection. Mice were supplemented with a diet containing lignans seven days before
an intraperitoneal injection of crocidolite asbestos and three days after asbestos exposure; they were
evaluated for abdominal inflammation, pro-inflammatory/pro-fibrogenic cytokine release, WBC gene
expression changes, and oxidative and nitrosative stress in peritoneal lavage fluid. The results showed
that dietary lignan administration diminished acute inflammation by decreasing the number of WBCs
and the release of IL-1β, IL-6, HMGB1, and TNF-α pro-inflammatory cytokines and pro-fibrogenic
active TGF-β1. Furthermore, lignan acted as an anti-oxidant by decreasing mRNA levels of inducible
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nitric oxide synthase, and thus nitrosative and oxidative stress, and by increasing the expression of the
Nrf2-regulated anti-oxidant enzymes, HO-1, Nqo1 and Gstm1 [42].
In a preliminary study, Martinotti et al. demonstrated that the combined treatment with EGCG,
ascorbate, and gemcitabine (AND) synergistically affected the viability of MM cells [149]. Next, the
same authors showed that AND treatment increased DAPK2 (Death-Associated Protein Kinase 2), a
calcium- and calmodulin-dependent regulator of apoptosis and tumor suppressor, and TNSFR11B
expression. The TNSFR11B gene encodes a cytokine receptor belonging to the TNF receptor family,
called osteoprotegerin (OPG). OPG acts as receptor for RANK ligand, inhibiting RANK-dependent
activation of NF-κB. Furthermore, they observed a decreased expression of TNFAIP3 (tumor necrosis
factor-α-induced protein 3), an inhibitor of NF-κB activation and TNF-mediated apoptosis, typically
up-regulated in inflammation and in tumors. In this study, they found a down-regulated TNFAIP3
expression because AND treatment decreased p65 subunit of NF-κB. Hence, the combined treatment
induced a non-inflammatory apoptosis [150].
The transcription factor Specificity protein 1 (Sp1) is highly expressed in different cancers and is
associated with poor prognosis. Sp1 modulates the expression of oncogenes and tumor suppressors,
as well as genes involved in proliferation, differentiation, the DNA damage response, apoptosis,
senescence, and angiogenesis and it is also implicated in inflammation and genomic instability [151].
Lee et al. showed that resveratrol decreased the Sp1 expression and down-regulated
Sp1-dependent gene expression in MM. They observed a decreased tumor volume and an increased
number of caspase-3-positive cells after intraperitoneal treatment with resveratrol [152]. In another
study, it has been demonstrated that the combined treatment of clofarabine and resveratrol decreased
levels of Sp1, p-Akt, c-Met, cyclin D1, and p21 [153].
Similarly, Chae et al. found that 20–80 µM quercetin suppressed the Sp1 expression and modulated
the target genes, as cyclin D1, Mcl-1 (myeloid cell leukemia), and survivin in MM. Furthermore,
quercetin induced apoptosis through the Bid, caspase-3, and PARP cleavage, the up-regulation of Bax,
and down-regulation of Bcl-xL in MSTO-211H cells [154].
In another study, the same authors focused on the anticancer effects of honokiol (HNK), a
pharmacologically active component found in the traditional Chinese medicinal herb, Magnolia species.
It has been observed that HNK inhibited MM cell growth, down-regulated Sp1 expression and Sp1
target transcription factors, including cyclin D1, Mcl-1, and survivin, and induced the apoptosis by
increasing Bax, reducing Bid and Bcl-xL and activating caspase-3 and PARP [155].
Kim et al. found that licochalcone A (LCA), a natural product derived from the Glycyrrhiza inflata,
regulated the cell growth and down-regulated the Sp1 expression in MSTO-211H and H28 cell lines.
Furthermore, LCA down-regulated the expression of Sp1 downstream genes, as cyclin D1, Mcl1 and
survivin. Like quercetin and honokiol, LCA increased Bax and decreased Bcl-2 expression, inducing
the mitochondrial apoptotic pathway [156].
Lee et al. demonstrated that hesperidin, a flavanone presents in citrus fruits, inhibited the
cell growth and down-regulated the SP1 expression in MSTO-211H cells. Hesperidin significantly
suppressed mRNA and protein levels of Sp1 and regulated the expression of p27, p21, cyclin D1,
Mcl-1, and survivin. Furthermore, hesperidin induced the apoptosis pathway through cleavages of
Bid, caspase-3, and PARP, and up-regulation of Bax and down-regulation of Bcl-xL [157]. Similarly,
the same authors showed that cafestol and kahweol, two diterpenes present in the typical bean of
Coffea Arabica, induced apoptosis and suppressed the Sp1 protein levels in MSTO-211H cells. These
compounds modulated the expression of genes regulated by Sp1, including cyclin D1, Mcl-1, and
survivin. Furthermore, the cafestol treatment induced the cleavage of Bid, caspase-3, and PARP, and
the kahweol treatment up-regulated Bax and down-regulated Bcl-xL [158].
The effect of a novel mixture containing lysine, proline, ascorbic acid, and green tea extract has
been investigated by Roomi et al. in MM cell line MSTO-211H. They demonstrated that this mixture
was able to inhibit MMP secretion and invasion and thus is a promising candidate for therapeutic use
in the treatment of MM [159].
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Effects of polyphenols on mediators of inflammation in MM are summarized in Table 2.
Table 2. Effects of polyphenols on production of mediators of inflammation in MM.
Polyphenols Cell Type or AnimalModel Effects on Inflammation Ref.
Curcumin
H-MESO, NCI-2052,
NCI-H2452, MSTO-211H,
and NCI-H28 cells
Ò Caspase-1
[108,148]
Ò pro-IL-1β and block of maturation
of IL-1 β
Ò NLRP3
Ó NF-κB, TRL, and IL-1 pathways
Ò PIAS-3
Ó p-STAT-3
Butein MSTO-211H, NCI-H28,
NCI-H2052
Ó NF-κB, p-STAT-3
[146]ÓVEGF
Ó IL-6, IL-8
Flaxseed Lignans MM-prone Nf2
+/mut
mice
Ó IL-1β, IL-6, HMGB1, TNF-α,
TGF-β1 [42]
Ò Nrf2-regulated anti-oxidant
enzymes
EGCG + Ascorbate +
Gemcitabine (AND) REN cells
Ò DAPK2
[150]
Ò TNSFR11B
Ó TNFAIP3
Ó NF-κB pathway
Resveratrol MSTO-211H cells
Ó Sp1, p21, p27, cyclin D1, Mcl-1
[152]Ó survivin
Ò Apoptosis
Resveratrol +
Clofarabine
MSTO-211H cells
Ó Sp1, p-Akt
[153]Ó c-Met, cyclin D1, p21
Quercetin MSTO-211H cells
Ó Sp1, cyclin D1, Mcl-1, survivin
[154]Ò Apoptosis
Honokiol MSTO-211H cells
Ó Sp1
[155]Ó cyclin D1, Mcl-1, survivin
Ò Apoptosis
Licochalcone A MSTO-211H and H28
cells
Ó Sp1
[156]Ó cyclin D1, Mcl-1, survivin
Ò Apoptosis
Hesperidin MSTO-211H cells
Ó Sp1
[157]Ó p27, p21, cyclin D1, Mcl-1,
survivin
Ò Apoptosis
Cafestol and kahweol MSTO-211H cells
Ó Sp1, cyclin D1, Mcl-1, survivin
[158]Ò Apoptosis
Ó: decrease; Ò: increase.
6. Conclusions
The immune system, and in particular inflammation, has an essential role in the development
of MM. A long-lasting inflammatory response orchestrated by mesothelial cells contributes to the
initiation, promotion, and progression of mesothelial cells into MM. Polyphenols possess important
anti-inflammatory properties by regulating innate and adaptive immunity through the modulation of
different mediators of inflammation and also by acting as an immune surveillance mechanism against
cancers through the regulation of apoptosis. Furthermore, polyphenols possess a pro-oxidant activity,
which could be used against cancer. In fact, in the last few years the use of ROS-generating agents
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against cancer is an emerging strategy to kill cancer cells, since it has been observed that ROS contribute
to the cytotoxic activity of some chemotherapeutics and that cancer cells are more susceptible to ROS
than normal cells.
Accordingly, the local or systemic administration of polyphenols might reduce the production of
pro-inflammatory molecules by targeting signal transduction pathways or ROS and RNS in order to
prevent MM. On the other hand, the administration of polyphenols might also induce MM cell death
to limit tumor growth.
Furthermore, MM is a tumor arising from the mesothelial cell linings of the serous membranes,
thus the local administration of polyphenols in the serous cavity might be a better strategy to treat
MM, because in this way polyphenols could bypass biotransformation and could reach an effective
dose directly available at the site of tumor.
Thus the use of polyphenols might represent a promising strategy to contrast the development
and/or to prevent MM.
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